Published:
NexMed Announces Third Quarter 2009 Financial Results Conference Call
EAST WINDSOR, N.J. - (BUSINESS WIRE) - NexMed, Inc. (Nasdaq: NEXM), a developer of innovative topical products
based on the NexACT technology, today announced that
management will hold a conference call to discuss 2009 third quarter
financial results and ongoing corporate activities, on Tuesday, November
10, 2009 at 10:00 a.m. EST. The Company will file its Form 10-Q by the
end of business on Monday, November 9, 2009.
In addition, NexMed also announced that it is currently in late stage
contract negotiations to lease its facility. Mark Westgate, NexMed's
Chief Financial Officer stated, "If we successfully close this
transaction, our monthly cash burn will drop significantly. The tenant
will assume all building expenses and the rental income will exceed our
mortgage obligations, thereby resulting in a positive cash flow for us."
The call can be accessed in the U.S. by dialing 877-407-9205 and outside
of the U.S. by dialing 201-689-8054 and asking the conference operator
for the NexMed Conference Call. The teleconference replay is available
for one week by dialing in the U.S. 877-660-6853 and outside of the U.S.
by dialing 201-612-7415. Replay pass codes 286 and 337111 are both
required for playback. The conference call will also be Webcast live at
URL http://www.investorcalendar.com/IC/CEPage.asp?ID=151979.
The Webcast replay will be available for three months.
About NexMed
NexMed's pipeline includes a late stage terbinafine treatment for
onychomycosis, a late stage alprostadil treatment for erectile
dysfunction, a P 2 alprostadil treatment for female sexual arousal
disorder, and an early stage treatment for psoriasis. For further
information about NexMed, go to www.nexmed.com.
Statements under the Private Securities Litigation Reform Act: with the
exception of the historical information contained in this release, the
matters described herein contain forward-looking statements that involve
risks and uncertainties that may individually or mutually impact the
matters herein described, including, but not limited to our ability to
successfully close on the leasing of our facility, entering into
development and commercialization agreements and obtaining regulatory
approval for our products under development, entering into a strategic
transaction for the company, pursuing growth opportunities, and/or other
factors, some of which are outside our control.
NexMed, Inc.
Mark Westgate, CFO, 609-371-8123, ext: 159
mwestgate@nexmed.com
or
Investor
Relations:
Rx Communications Group, LLC
Paula Schwartz,
917-322-2216
pschwartz@rxir.com
Copyright © 2009, Business Wire, Inc., All rights reserved.
Copyright © 2009, NewsBlaze,
Daily NewsTags: Business wire, Healthcare, new jersey, Health, Biotechnology, Pharmaceuticals
Search News
Daily News
